Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

Multiple natural killer (NK) cell-based anticancer therapies are currently under development. Here, we compare the efficiency of genetically modified NK-92 cells expressing chimeric antigen receptors (CARs) at killing NK cell-resistant B-lymphoid leukemia cells to the antibody-dependent cell-mediate...

Descripción completa

Detalles Bibliográficos
Autores principales: Boissel, Laurent, Betancur-Boissel, Monica, Lu, Weiquan, Krause, Daniela S, Van Etten, Richard A, Wels, Winfried S, Klingemann, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881109/
https://www.ncbi.nlm.nih.gov/pubmed/24404423
http://dx.doi.org/10.4161/onci.26527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881109/
https://www.ncbi.nlm.nih.gov/pubmed/24404423
http://dx.doi.org/10.4161/onci.26527

Ejemplares similares